Tirzepatide demonstrated superior weight loss efficacy compared to semaglutide in the SURMOUNT-5 trial, according to topline results released by Eli Lilly. (Learn More)
The 72-week study involved 751 patients with obesity or overweight and at least one weight-related comorbidity.
Tirzepatide users experienced an average 20.2% reduction in body weight, while semaglutide users achieved a 13.7% reduction.
This represents a 47% greater weight loss with tirzepatide compared to semaglutide.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, while semaglutide is solely a GLP-1 receptor agonist.
Over 31% of tirzepatide patients achieved a 25% reduction in body weight, compared to 16.1% of semaglutide patients.
Both drugs primarily caused mild-to-moderate gastrointestinal issues as side effects.
Tirzepatide (Zepbound) and semaglutide (Wegovy) are both FDA-approved for chronic weight management in adults with obesity or overweight and a weight-related condition.
Semaglutide has an additional indication for cardiovascular disease prevention based on the SELECT trial.
Both drugs are also approved under different names (Mounjaro and Ozempic, respectively) for type 2 diabetes treatment.
SUMMIT and STEP-HFpEF trials have shown the effectiveness of tirzepatide and semaglutide in patients with heart failure with preserved ejection (HFpEF).
Eli Lilly is conducting the SURPASS-CVOT study, comparing tirzepatide and dulaglutide in patients with type 2 diabetes.
Full SURMOUNT-5 results are expected to be published and presented at a major medical meeting in 2025.
Key Takeaways:
- Tirzepatide showed 47% greater weight loss than semaglutide over 72 weeks
- Tirzepatide users lost an average of 20.2% body weight vs 13.7% with semaglutide
- Both drugs are FDA-approved for chronic weight management and type 2 diabetes treatment
- Full SURMOUNT-5 results are anticipated in 2025
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.